Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Present at the Stifel 2022 Healthcare Conference

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
November 03, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
November 01, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

Approximately 160 to 170 Subjects in Total Are Expected to Complete the Clinical Study;Approximately 100 Subjects Have Completed All Study Assessments to Date Topline Data of Phase 2b RESPOND Study...
October 17, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study

Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring...
October 10, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

SAN DIEGO, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food & Drug Administration (FDA) approved...
September 15, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Participate in Two Upcoming Conferences

SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
September 06, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Participate in H.C. Wainwright 24th Annual Global Investment Conference

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
August 29, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Study Enrollment Expected to Complete in 4Q-2022 with Approximately 150 Subjects Topline Data of Phase 2b RESPOND Study Targeted for 2Q-2023 If clinical development is successful, Sildenafil Cream,...
August 24, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience, Inc. Announces Global Licensing Rights to the Novel Antimicrobial Glycerol Monolaurate for Vaginal Health

SAN DIEGO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it has entered into a license agreement with Hennepin...
August 09, 2022 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update

June 30, 2022: $32.1 million in cash and cash equivalentsJuly 2022: approximately $18.0 million in cash received subsequent to quarter-end: $10.0 million upfront license fee under global license...